Avalo Therapeutics, Inc.
AVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $60,395 | $2,527 | $47,419 | $177,191 |
| - Cash | $134,546 | $7,415 | $13,172 | $54,585 |
| + Debt | $2,918 | $537 | $19,416 | $32,833 |
| Enterprise Value | -$71,233 | -$4,351 | $53,663 | $155,439 |
| Revenue | $441 | $1,924 | $18,051 | $5,398 |
| % Growth | -77.1% | -89.3% | 234.4% | – |
| Gross Profit | $807 | $640 | $14,617 | $3,907 |
| % Margin | 183% | 33.3% | 81% | 72.4% |
| EBITDA | -$68,343 | -$23,286 | -$37,274 | -$80,477 |
| % Margin | -15,497.3% | -1,210.3% | -206.5% | -1,490.9% |
| Net Income | -$35,129 | -$31,544 | -$41,658 | -$84,376 |
| % Margin | -7,965.8% | -1,639.5% | -230.8% | -1,563.1% |
| EPS Diluted | -3.26 | -113.58 | -1,062.65 | -2,330.66 |
| % Growth | 97.1% | 89.3% | 54.4% | – |
| Operating Cash Flow | -$49,056 | -$30,680 | -$26,751 | -$70,892 |
| Capital Expenditures | $0 | -$158 | -$95 | -$113 |
| Free Cash Flow | -$49,056 | -$30,838 | -$26,846 | -$71,005 |